Sarm1 enzyme activity inhibitor and application thereof
US-2024368168-A1 · Nov 7, 2024 · US
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9006281B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9006281-B2 |
| Application number | US-201313826186-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2013 |
| Priority date | Dec 31, 2008 |
| Publication date | Apr 14, 2015 |
| Grant date | Apr 14, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating irritable bowel syndrome in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: 2. The method of claim 1 , comprising administering the compound…
Assignees
Inventors
Classifications
- A61K31/4725Primary
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- C07D217/14Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9006281B2 cover?
- The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure
- Who is the assignee on this patent?
- Ardelyx Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4725. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).